A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis

Study Description

A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease that causes inflammation of the membranes that surround the brain and the spinal cord (meninges). TBM is caused by the bacterium Mycobacterium tuberculosis, which can be found elsewhere in the body, usually the lungs, but can travel via the bloodstream to the meninges, where the bacteria cause TBM.

This trial will compare a new experimental regimen of anti-TBM medicines taken over a 6-month time period with the current standard of care regimen of anti-TBM medicines taken over a 9-month time period.

Study Purpose

  • Better treatments for TBM are needed. This study will look at the safety and tolerability (having a reaction or side effects from the medicines) of the regimens and how well the experimental 6-month regimen does compared to the standard 9-month regimen.
  • The study will also measure the level of the drugs in the blood and cerebrospinal fluid (CSF).

Target Participant

  • Age 15 years and older
  • Definite, probable, or possible TBM diagnosis from testing performed as part of routine care within 21 days of entering the study
  • Cannot have taken more than 14 days of anti-TB medications
  • Cannot have current or prior drug-resistant TB infection
  • Living with or without HIV
  • If with HIV:
  • May need to switch to an acceptable anti-HIV regimen
  • May not initiate anti-HIV treatment during first 4 weeks of study

Categories

Location
Topic

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More